Patents by Inventor Katherine M. Fowler

Katherine M. Fowler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrimidinone derivatives as CDC7 inhibitors
    Patent number: 11766434
    Abstract: The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.
    Type: Grant
    Filed: April 29, 2021
    Date of Patent: September 26, 2023
    Assignee: Cancer Research Technology Limited
    Inventors: Emma L. Carswell, Mark David Charles, Chukuemeka Tennyson Ekwuru, Frederic Elustondo, Katherine M. Fowler, Gregory R. Ott, Jonathan R. Roffey, Joanna L. Brookfield, Daniel James Ford, Mathew L. Calder
  • PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS
    Publication number: 20220079942
    Abstract: The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.
    Type: Application
    Filed: April 29, 2021
    Publication date: March 17, 2022
    Inventors: Emma L. Carswell, Mark David Charles, Chukuemeka Tennyson Ekwuru, Frederic Elustondo, Katherine M. Fowler, Gregory R. Ott, Jonathan R. Roffey, Joanna L. Brookfield, Daniel James Ford, Mathew L. Calder
  • Pyrimidinone derivatives as Cdc7 inhibitors
    Patent number: 11020396
    Abstract: The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: June 1, 2021
    Assignee: Cancer Research Technology Limited
    Inventors: Emma L. Carswell, Mark David Charles, Chukuemeka Tennyson Ekwuru, Frederic Elustondo, Katherine M. Fowler, Gregory R. Ott, Jonathan R. Roffey, Joanna L. Brookfield, Daniel James Ford, Mathew L. Calder
  • Preparation and uses of pyrimidinone derivatives
    Patent number: 10919896
    Abstract: The present invention relates to compounds of formula (I), and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity: wherein X, R1, R2, and n are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: February 16, 2021
    Assignee: Cancer Research Technology Limited
    Inventors: Emma L. Carswell, Mark David Charles, Anne Cochi, Benjamin J. Dugan, Chukuemeka Tennyson Ekwuru, Fred Elustondo, Katherine M. Fowler, Frederic Georges Marie Leroux, Nathaniel J. T. Monck, Gregory R. Ott, Jonathan R. Roffey, Gurwinder Sidhu, Neil Tremayne
  • PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE
    Publication number: 20200123157
    Abstract: The present invention relates to compounds of formula (I), and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity: wherein X, R1, R2, and n are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.
    Type: Application
    Filed: September 22, 2017
    Publication date: April 23, 2020
    Inventors: Emma L. Carswell, Mark David Charles, Anne Cochi, Benjamin J. Dugan, Chukuemeka Tennyson Ekwuru, Fred Elustondo, Katherine M. Fowler, Frederic Georges Marie Leroux, Nathaniel J.T. Monck, Gregory R. Ott, Jonathan R. Roffey, Gurwinder Sidhu, Neil Tremayne
  • PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS
    Publication number: 20190336502
    Abstract: The present invention relates to compounds of formula I as defined herein, and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity. The present invention also relates to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Cdc7 kinase activity is implicated.
    Type: Application
    Filed: November 7, 2017
    Publication date: November 7, 2019
    Inventors: Emma L. Carswell, Mark David Charles, Chukuemeka Tennyson Ekwuru, Frederic Elustondo, Katherine M. Fowler, Gregory R. Ott, Jonathan R. Roffey, Joanna L. Brookfield, Daniel James Ford, Mathew L. Calder
  • Azaquinazoline inhibitors of atypical protein kinase C
    Patent number: 10414763
    Abstract: The present application provides a compound of formula (I) and/or a salt thereof, wherein R1, G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders. Compositions comprising a compound of Formula (I) and/or a salt thereof are also provided.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: September 17, 2019
    Assignee: Cancer Research Technology Limited
    Inventors: Bruce D. Dorsey, Benjamin J. Dugan, Katherine M. Fowler, Robert L. Hudkins, Eugen F. Mesaros, Nathaniel J T Monck, Emma L. Morris, Ikeoluwa Olowoye, Gregory R. Ott, Gregoire A. Pave, Jonathan R. A. Roffey, Christelle N. Soudy, Craig A. Zificsak, Allison L. Zulli
  • Azaquinazoline inhibitors of Atypical protein Kinase C
    Patent number: 9914730
    Abstract: The present application provides azaquinazoline compounds as defined herein. This application further describes compositions comprising the same. These azaquinazoline compounds and their salts have atypical protein kinase C (“aPKC”) inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: March 13, 2018
    Assignee: Cancer Research Technology Limited
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Benjamin J Dugan, Katherine M. Fowler, Robert L Hudkins, Eugen F. Mesaros, Nathaniel J. T. Monck, Emma L. Morris, Ikeoluwa Olowoye, Gregory R. Ott, Gregoire A. Pave, Jonathan R. Roffey, Christelle N. Soudy, Ming Tao, Craig A. Zificsak, Allison L. Zulli
  • Azaquinazoline inhibitors of atypical protein kinase C
    Patent number: 9896446
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. This application further describes compositions comprising the same. Compounds of formula (I) and their salts have aPKC inhibitory activity, and may be used to treat proliferative diseases.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 20, 2018
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Benjamin J. Dugan, Robert L. Hudkins, Eugen F. Mesaros, Gregory R. Ott, Craig A. Zificsak, Allison L. Zulli, Ming Tao, Katherine M. Fowler, Emma L. Morris, Gregoire A. Pave, Jonathan R. A. Roffey, Nathaniel J. T. Monck, Christelle N. Soudy, Ikeoluwa Olowoye
  • Azaquinazoline Inhibitors of Atypical Protein Kinase C
    Publication number: 20160102094
    Abstract: The present application provides a compound of formula (1) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. This application further describes compositions comprising the same. Compounds of formula (I) and their salts have aPKC inhibitory activity, and may be used to treat proliferative diseases.
    Type: Application
    Filed: December 18, 2015
    Publication date: April 14, 2016
    Applicants: IGNYTA, INC., Cancer Research Technology Limited
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Benjamin J. Dugan, Robert L. Hudkins, Eugen F. Mesaros, Gregory R. Ott, Craig A. Zificsak, Allison L. Zulli, Ming Tao, Katherine M. Fowler, Emma L. Morris, Gregoire A. Pave, Jonathan R.A. Roffey, Nathaneil J.T. Monck, Christelle N. Soudy, Ikeoluwa Olowoye
  • Azaquinazoline Inhibitors Of Atypical Protein Kinase C
    Publication number: 20150274720
    Abstract: The present application provides a compound of formula (I) and/or a salt thereof, wherein R1, G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders. Compositions comprising a compound of Formula (I) and/or a salt thereof are also provided.
    Type: Application
    Filed: March 25, 2015
    Publication date: October 1, 2015
    Inventors: Bruce D. Dorsey, Benjamin J. Dugan, Katherine M. Fowler, Robert L. Hudkins, Eugen F. Mesaros, Nathaniel JT Monck, Emma L. Morris, Ikeoluwa Olowoye, Gregory R. Ott, Gregoire A. Pave, Jonathan R.A. Roffey, Christelle N. Soudy, Craig A. Zificsak, Allison L. Zulli
  • Azaquinazoline Inhibitors of Atypical Protein Kinase C
    Publication number: 20140113882
    Abstract: The present application provides a compound of formula (I) or a salt thereof, wherein R7, R8, R9, G, and X are as defined herein. This application further describes compositions comprising the same. Compounds of formula (I) and their salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: September 27, 2013
    Publication date: April 24, 2014
    Applicants: Cancer Research Technology Limited, Cephalon, Inc.
    Inventors: Henry J. Breslin, Bruce D. Dorsey, Benjamin J. Dugan, Katherine M. Fowler, Robert L. Hudkins, Eugen F. Mesaros, Nathaniel J.T. Monck, Emma L. Morris, Ikeoluwa Olowoye, Gregory R. Ott, Gregoire A. Pave, Jonathan R. Roffey, Christelle N. Soudy, Ming Tao, Craig A. Zificsak, Allison L. Zulli